Journal
AUTOIMMUNITY REVIEWS
Volume 18, Issue 12, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.autrev.2019.102403
Keywords
Systemic sclerosis; Corticosteroids; Risk; Efficacy
Categories
Ask authors/readers for more resources
In systemic sclerosis (SSc), the use of corticosteroids (CS) is controversial due to their association with sclerderma renal crisis (SRC). However, patients with very early and early disease, characterised by main inflammatory component, may benefit from CS therapy. The aim of this review is to discuss pros and cons of CS treatment in SSc, providing current evidence about the use of CS in SSc. Moreover, we discuss also the underlying pathogenetic mechanisms that may be the background for the potential harms and efficacy of CS in SSc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available